Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Category: #health  By Saipriya Iyer  Date: 2019-11-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac failure.

The results were presented on November 7, 2019, at the American Heart Association Annual Meeting. Triple Gene is owned is a majorly owned subsidiary of Intrexon Corporation.

According to Thomas D. Reed, Co-founder and Managing Director at Triple Gene, the data proposes that the combination of the company’s newly developed non-integrating naked plasmid DNA with focused cardiac delivery supported by Retrograde Coronary Sinus Infusion carries the ability to open a new biologics treatment model. It could be used for the treatment of cardiovascular diseases, he further added.

Triple Gene’s Co-founder and Clinical Director, Amit N. Patel, MD, MS, was reportedly quoted stating that 12 patients in the clinical trial have received the drug dosage between the two clinical sites at the University of Arizona, Tucson and The Christ Hospital, Cincinnati. Presently, the company is exploring clinical study designs that consider repetitive dosing along with additional orphan-like heart failure subtypes.

For the record, the investigational therapy by Triple Gene utilizes the non-viral delivery mechanism of a controlled multigenic plasmid developed to express human S100A1, VEGF165 and SDF-1a gene products that may affect progenitor cell recruitment, calcium handling, and angiogenesis. It also targets the fundamental  mechanisms associated with pathological myocardial remodeling. Further, the plasmid treatment is rendered through RCSI, which facilitates cardiac-specific delivery to the heart’s ventricle.

About Triple-Gene

Triple Gene primarily focuses on developing controllable, targeted and multigenic gene therapies to diagnose cardiovascular diseases. The company’s main product is a non-viral clinical gene therapy candidate that drives expression of three candidate genes which are effectively associated with heart failure. 

 

 

Source Credits: https://3gtx.com/wp-content/uploads/2019/11/Triple-Gene_Presented_Preliminary_Phase_1_Trial_Data_at_AHA_Annual_Meeting.pdf



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Walgreens Boots Alliance inks deal with McKesson Corporation
Walgreens Boots Alliance inks deal with McKesson Corporation
By Saipriya Iyer

Walgreens Boots Alliance, an American holding company headquartered in Illinois inked a deal with Mckesson Corporation, a German healthcare and pharmaceutical company to transpire a joint venture (JV) which will bolste...

Amphivena announces initial data from Phase 1 study of AMV564
Amphivena announces initial data from Phase 1 study of AMV564
By Saipriya Iyer

Amphivena Therapeutics, Inc., a clinical stage immuno-oncology firm developing T cell engager therapies for cancer, has recently presented data from Phase 1 trial of AMV564, a bivalent T cell engager clinical candidate...

Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
By Saipriya Iyer

Sanofi, a renowned France based multinational pharmaceutical company, reportedly announced that it would be acquiring California based biotechnology firm, Synthorx, for $2.5 billion. Sanofi offered to purchase all outs...